Shots: The P-III ECZTRA 6 trial evaluates the efficacy & safety of tralokinumab (150/300mg, q2w) as monothx. vs PBO in 301 patients aged 12-17yrs. with mod. to sev. AD who […]readmore
Tags : Atopic Dermatitis
Shots: The approval is based on the P-III clinical trial program including Measure Up 1/2/AD Up that evaluates the efficacy & safety of Rinvoq (qd) as monothx. with TCS vs […]readmore
Shots: The P-IIa study evaluates amlitelimab (IV, low/high dose, q4w over 12wks.) vs PBO in 88 patients with mod. to sev. AD inadequately controlled with topical therapies The co-primary EPs […]readmore
Shots: The approval is based on the TRuE-AD clinical trial program which consists of two P-III studies i.e., TRuE-AD1 & 2 evaluating the safety and efficacy of Opzelura cream (1.5%, […]readmore
Shots: The first patient has been dosed in a P-III program that consists of P-III ADORING 1/2 and long-term extension ADORING 3 study evaluates the safety and efficacy of tapinarof […]readmore
Shots: The P-II clinical trial evaluates FB-401 vs PBO in patients with AD The trial did not meet its 1EPs of EASI-50 (50% improvement in AD disease severity as measured […]readmore
Shots: The head-to-head P-III JADE DARE study involves assessing the efficacy of Abrocitinib (200mg, qd, PO) vs dupilumab (300mg, SC, q2w followed by 600mg induction dose) in adult patients on […]readmore
Shots: The P-II/III LIBERTY AD PRESCHOOL (part B) involves assessing the efficacy & safety of Dupixent (200/300mg) + low-potency TCS vs TCS alone in 162 children aged 6mos. to 5 […]readmore
Shots: The ongoing P-III ADvocate 1 & 2 studies evaluate lebrikizumab as monothx. vs PBO in adult & adolescent patients aged 12 to less than 18 yrs. with mod. to […]readmore
Shots: The opinion is based on data from the 3 P-III studies i.e Measure Up 1, Measure Up 2 & AD Up evaluating the safety & efficacy of Rinvoq (15/30 […]readmore